Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Crucell Terug naar discussie overzicht

Draadje pubmed.

127 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste | Omlaag ↓
  1. [verwijderd] 8 april 2009 21:35
    Ken nog een mop:

    Study protocol
    Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance

    Christian Schaetti , Raymond Hutubessy , Said M Ali , Al Pach , Mitchell G Weiss , Claire-Lise Chaignat and Ahmed M Khatib

    BMC Public Health 2009, 9:99doi:10.1186/1471-2458-9-99


    Published: 7 April 2009

    Abstract (provisional)
    Background
    Cholera remains a serious public health problem in low-income countries despite efforts in the past to promote oral rehydration therapy as major treatment. In 2007, the majority of worldwide cases (94%) and deaths (99%) were reported from Africa. To improve cholera control efforts in addition to maintaining and improving existing water supply, sanitation and hygiene behaviour measures, the World Health Organization has recently started to consider the use of vaccines as an additional public health tool. To assess this new approach in endemic settings, a project was launched in Zanzibar to vaccinate 50,000 individuals living in communities at high risk of cholera with an oral two-dose vaccine (Dukoral(R)). Immunisation programmes in low-income countries have suffered a reduced coverage or were even brought to a halt because of an ignorance of local realities. To ensure the success of vaccination campaigns, implementers have to consider community-held perceptions and behaviours regarding the infectious disease and the vaccine of interest. The main aim of this study is to provide advice to the Ministry of Health and Social Welfare of Zanzibar regarding routine introduction of an oral cholera vaccine from a socioeconomic and behavioural perspective as part of a long-term development for a sustained cholera prevention strategy.

    Methods
    Qualitative and quantitative methods of health social science research will be applied on four stakeholder levels before and after the mass vaccination campaign. Rapid assessment individual interviews and focus groups will be used to describe cholera- and vaccine-related views of policy makers, health care professionals and community representatives. The cultural epidemiological approach will be employed on the individual household resident level in a repeated cross-sectional design to estimate determinants of anticipated and actual oral cholera vaccine acceptance.

    Discussion
    The study presented here is designed to inform about people's perceptions regarding cholera and about socioeconomic and behavioural factors determining anticipated and actual oral cholera vaccine acceptance in Zanzibar. Its pre- and post-intervention design using a mixed-methods approach on different stakeholder levels in communities at high risk of cholera outbreaks will ensure the collection of locally valid data relevant for public health action and planning.

    www.biomedcentral.com/1471-2458/9/99
  2. MeawandMoo1 24 april 2009 23:05
    Zo..
    Crucell heeft weer een antal monoclonal antibodies ontdekt met neutraliserende werking na oplopen van een infectie.
    Vergelijking met Rabies:
    Ook hier overleven de meeste muisjes na ontvangst van een dodelijke infectie.

    quote:

    Crucell schreef:

    Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo,
    Human Monoclonal Antibodies Induced by Natural Infection Against West Nile Virus Neutralize at a Post-Attachment Step.

    Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS.
    Departments of Pathology and Immunology, Molecular Microbiology, Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands; Crucell Holland B.V., 2301 CA, Leiden, The Netherlands; Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

    West Nile virus (WNV) is a neurotropic flavivirus that is now a primary cause of epidemic encephalitis in North America. Studies in mice have demonstrated that the humoral immune response against WNV limits primary infection and protects against a secondary challenge. The most potent neutralizing mouse monoclonal antibodies (MAbs) recognize an epitope on the lateral ridge of domain III (DIII-lr) of the envelope (E) protein. However, studies with serum from human patients show that antibodies against the DIII-lr epitope comprise at best, a minor component of the human anti-WNV antibody response. Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo, and yet poorly recognize recombinant forms of E protein. Instead, CR4348 and CR4354 bind determinants on intact WNV virions and subviral particles in a pH-sensitive manner, and neutralization is altered by mutations at the dimer interface in domain II and the hinge between domains I and II, respectively. CR4348 and CR4354 human MAbs neutralize infection at a post-attachment step in the viral lifecycle, likely by inhibiting acid-induced fusion within the endosome.

    www.ncbi.nlm.nih.gov/pubmed/19386704?...
  3. [verwijderd] 25 april 2009 00:13
    Aanbevolen!
    J Virol. 2009 Apr 22.
    quote:

    MeawandMoo1 schreef:

    [quote=Crucell]
    Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo,
    [/quote]
    Human Monoclonal Antibodies Induced by Natural Infection Against West Nile Virus Neutralize at a Post-Attachment Step.
    Weer heel mooi! Commercieel wellicht minder interessant dan H5N1 flu of Rabies, maar toch weer wel mooi omdat het antibodies zijn.
    Specifiek voor zo'n net wel /net niet virus als WestNile, lijkt het waarschijnlijk dat slechts risico-groepen inge-ent gaan worden met een ontwikkeld vaccin (november 2007 - Acambis partnert met Sanofi). Dan is het toch ook wel heel fijn dat er ook een post-exposure antibody komt, temeer daar er nog geen officiele medicijnen tegen westnile infectie zijn.

    Leuk, geeft vertrouwen in Crucell's antibody capaciteiten. Voor de koerskijkers: kVerwacht geen grote effecten.

    Nu overigens ook snel testen of Crucell's anti-flu antibodies ook tegen swine flu werken.
  4. flosz 25 april 2009 09:32
    Uit het verleden mbt WNV-vaccin:

    Development discontinued
    It has been decided that these programs will no longer be continued. Crucell has come to the conclusion that the commercial and market opportunities for its West Nile products are not as attractive as other products in Crucell's pipeline.

    Ook het Nederlandse Crucell ontwikkelde
    een vaccin tegen het WNV. Het Nederlands
    Vaccin Instituut heeft voor Crucell
    zelfs een hoeveelheid van het vaccin
    geproduceerd. Na succesvolle resultaten
    bij ganzen en een veelbelovend klinisch
    onderzoek, trok Crucell onlangs de stekker
    uit het project, waarschijnlijk door
    de sterke concurrentie van Acambis en
    Sanofi Pasteur.
    www.rivm.nl/cib/binaries/VastePriknr2...

    West Nile–What happened?
    Disease incidence declined
    »Future epidemiology: intermittent epidemic years but at uncertain interval
    »‘Place’ disease—affected areas with higher incidence but not sufficiently predictable year to year to warrant vaccine policy
    »Media coverage and public concern declined
    »Vaccine candidates in ‘Valley of Death’--$100+ million for licensed product with uncertain market
    »Uncertain ACIP recommendation, reimbursement policy (e.g., Lyme disease vaccine)
    »Regulatory pathway unclear (field trials vs. Animal Rule)
    »No Government funding mechanism available for advanced development
    »No Under these circumstances, industry interest declined
    »Not dead yet but dying

    Lessons for industry

    »SARS, Chikungunya, West Nile emergences sparked new technology and product development efforts
    »These have not been sustainable
    »High costs with uncertain returns
    »Opportunity costs
    »Government support ceases at early stage R&D
    »Increasingly demanding regulatory environment and advanced development costs
    »No Government funding for advanced development
    »No sustainable revenue model

    web.mit.edu/ssp/seminars/Monath%20pre...

  5. flosz 29 april 2009 15:44
    Expert Rev Vaccines. 2009 May;8(5):577-92

    Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects.

    Radosević K, Rodriguez A, Lemckert A, Goudsmit J.
    Immunology and Proof of Concept, Innovation & Discovery Lab, Crucell Holland BV, Leiden, The Netherlands. katarina.radosevic@crucell.com

    Classical vaccination approaches, based on a single vaccine administered in a homologous prime-boost schedule and optimized to induce primarily neutralizing antibodies, are unlikely to be sufficiently efficacious to prevent TB, malaria or HIV infections. Novel vaccines, capable of inducing a more powerful immune response, in particular T-cell immunity, are desperately needed. Combining different vaccine modalities that are able to complement each other and induce broad and sustainable immunity is a promising approach. This review provides an overview of heterologous prime-boost vaccination modalities currently in development for the 'big three' poverty-related diseases and emphasizes the need for innovative vaccination approaches

    www.ncbi.nlm.nih.gov/pubmed/19397415
  6. flosz 7 mei 2009 14:18
    Arch Pharm Res. 2009 Apr;32(4):465-80. Epub 2009 Apr 29.

    Innovative vaccine production technologies: the evolution and value of vaccine production technologies.

    Bae K, Choi J, Jang Y, Ahn S, Hur B.
    Vaccine Research Institute, CrucellBerna Biotech Korea, Yongin, 449-903, Korea. kyungdong.bae@crucell.kr

    This review paper provides an overview of innovative technologies designed to produce bacterial, viral, recombinant subunit, and polysaccharide vaccines, as well as combination vaccines. Advances in this field are illustrated by vaccines against DTP (diphtheria-tetanus-pertussis), influenza, hepatitis B (HepB) and typhoid fever. In addition, technological trends regarding antigens, adjuvants, and preservatives in vaccines are discussed. The progress achieved in vaccine production technologies is especially important for improving the protection of vulnerable populations against infectious diseases. These at-risk groups include infants, the elderly and immunocompromized individuals, as well as people living in developing countries or emerging economies.
    PMID: 19407962
    www.ncbi.nlm.nih.gov/pubmed/19407962
  7. flosz 13 mei 2009 07:02
    Blood. 2009 May 8.

    Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

    Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH, Baker AH.
    British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.

    Recent studies have demonstrated the importance of coagulation factor X (FX) in adenovirus (Ad) serotype 5-mediated liver transduction in vivo. FX binds to the adenovirus hexon hypervariable regions (HVRs). Here, we perform a systematic analysis of FX binding to Ad5 HVRs 5 and 7, identifying domains and amino acids critical for this interaction. We constructed a model of the Ad5-FX interaction employing crystallographic and cryoelectron microscopic data to identify contact points. Exchanging Ad5 HVR5 or HVR7 from Ad5 to Ad26 (which does not bind FX) diminished FX binding as analysed by surface plasmon resonance, gene delivery in vitro and liver transduction in vivo. Exchanging Ad5-HVR5 for Ad26-HVR5 produced deficient virus maturation. Importantly, defined mutagenesis of just two amino acids in Ad5-HVR5 circumvented this and was sufficient to block liver gene transfer. Additionally, mutation of 4 amino acids in Ad5-HVR7 or a single mutation at position 451 also blocked FX-mediated effects in vitro and in vivo. We therefore define the regions and amino acids on the Ad5 hexon that bind with high affinity to FX thereby better defining adenovirus infectivity pathways. These vectors may be useful for gene therapy applications where evasion of liver transduction is a prerequisite.
    www.ncbi.nlm.nih.gov/pubmed/19429866
  8. MeawandMoo1 18 mei 2009 01:44
    Suitability of PER.C6((R)) cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

    Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, de Leeuw O, Cornelissen L, Goudsmit J, Barclay W.
    Crucell Holland BV, Leiden, The Netherlands.

    Reverse genetics, the generation of influenza viruses from cDNA, presents a rapid method for creating vaccine strains. The technique necessitates the use of cultured cells. Due to technical and regulatory requirements, the choice of cell lines for production of human influenza vaccines is limited. PER.C6((R)) cells, among the most extensively characterized and documented cells, support growth of all influenza viruses tested to date, and can be grown to high densities in large bioreactors in the absence of serum or micro carriers. Here, the suitability of these cells for the generation of influenza viruses by reverse genetics was investigated. A range of viruses reflective of vaccine strains was rescued exclusively using PER.C6 cells by various transfection methods, including an animal component-free procedure. Furthermore, a whole inactivated vaccine carrying the HA and NA segments of A/HK/156/97 (H5N1) that was both rescued from and propagated on PER.C6 cells, conferred protection in a mouse model. Thus PER.C6 cells provide an attractive platform for generation of influenza vaccine strains via reverse genetics.
  9. flosz 20 mei 2009 07:53
    BMC Infect Dis. 2009 May 16
    Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

    Lopez-Gigosos R, Garcia-Fortea P, Calvo MJ, Reina E, Diez-Diaz R, Plaza E.

    ABSTRACT: BACKGROUND: Nowadays there is a debate about the indication of the oral whole-cell /recombinant B-subunit cholera vaccine (WC/rBS) in traveller's diarrhoea. However, a cost-benefit analysis based on real data has not been published. METHODS: A cost-effectiveness and cost-benefit study of the oral cholera vaccine (WC/rBS), Dukoral(R) for the prevention of traveller's diarrhoea (TD) was performed in subjects travelling to cholera risk areas. The effectiveness of WC/rBS vaccine in the prevention of TD was analyzed in 362 travellers attending two International Vaccination Centres in Spain between May and September 2005. RESULTS: The overall vaccine efficacy against TD was 42,6%. Direct healthcare-related costs as well as indirect costs (lost vacation days) subsequent to the disease were considered. Preventive vaccination against TD resulted in a mean saving of 79.26 E per traveller. CONCLUSIONS: According to the cost-benefit analysis performed, the recommendation for WC/rBS vaccination in subjects travelling to zones at risk of TD is beneficial for the traveller, regardless of trip duration and visited continent.
    www.ncbi.nlm.nih.gov/pubmed/19445712
  10. flosz 20 mei 2009 19:39
    Vaccine. 2009 May 15.

    Eleven years of Inflexal((R)) V - a virosomal adjuvanted influenza vaccine.

    Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, Glück R.

    Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal((R)) V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal((R)) V have been completed in which 3,920 subjects participated. During its decade on the market, Inflexal((R)) V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and its purity is reflected in the low ovalbumin content. By mimicking natural infection, the vaccine is highly efficacious. Inflexal((R)) V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children. This review presents and discusses the experience with Inflexal((R)) V during the past decade.

    www.ncbi.nlm.nih.gov/pubmed/19450630
  11. flosz 20 mei 2009 20:02
    Antimicrob Agents Chemother. 2009 May 18.

    Pharmacokinetics and safety profile of the human anti P. aeruginosa serotype O11 IgM monoclonal antibody KBPA-101 in healthy volunteers.

    Kenta Biotech, Rehhagstrasse 79, 3018 Bern, Switzerland; Berna Biotech AG, Rehhagstrasse 79, 3018 Bern, Switzerland; Swiss Pharma Contract, Lettenweg 118, 4123 Allschwil, Switzerland.

    KBPA-101 is a human monoclonal antibody of the IgM isotype directed against the O-polysaccharide moiety of P. aeruginosa serotype O11. This double blind, dose escalation study evaluated the safety and pharmacokinetics of KBPA-101 in 32 healthy volunteers aged 19 to 46 years. Each subject received a single intravenous infusion of KBPA-101 at a dose of 0.1, 0.4, 1.2 or 4 mg/kg of body weight or placebo infused over 2 hours. Plasma samples for pharmacokinetic assessment were taken before infusion as well as 0.25, 0.5, 1, 2, 2.5, 4, 6, 8, 12, 24, 36, 48h and 4, 7, 10, and 14 days after start of dosing. Plasma concentrations of KBPA-101 were detected with a mean maximum concentration of drug in plasma (Cmax) of 1877, 7571, 24923 and 83197 ng/mL following doses of 0.1, 0.4, 1.2, and 4.0 mg/kg body weight, respectively. The mean elimination half life (t1/2) was between 70 and 95 hours. The mean volume of distribution (Vz) was between 4.76 and 5.47 liters. Clearance (CL) ranged between 0.039 and 0.120 L/hr. At the highest dose of 4.0 mg/kg, plasma KBPA-101 levels were greater than 5000 ng/mL for 14 days. KBPA-101 exhibited linear kinetics across all doses. No anti-KBPA-101 antibodies were detected after dosing in any subject. Overall, the human monoclonal antibody KBPA-101 was well tolerated over the entire dose range in healthy volunteers and no serious adverse events have been reported.
    www.ncbi.nlm.nih.gov/pubmed/19451304

    Mbt Kenta Biotech, zie ook:
    www.iex.nl/forum/topic.asp?forum=228&...
  12. flosz 1 juni 2009 15:57
    BMC Microbiol. 2009 May 8;9:87

    Evaluation of the passage of Lactobacillus gasseri K7 and bifidobacteria from the stomach to intestines using a single reactor model.

    Ritter P, Kohler C, von Ah U.
    Agroscope Liebefeld-Posieux Research Station ALP, Schwarzenburgstrasse 161, CH-3003 Bern-Liebefeld, Switzerland. philipp.ritter@crucell.ch

    BACKGROUND: Probiotic bacteria are thought to play an important role in the digestive system and therefore have to survive the passage from stomach to intestines. Recently, a novel approach to simulate the passage from stomach to intestines in a single bioreactor was developed. The advantage of this automated one reactor system was the ability to test the influence of acid, bile salts and pancreatin.Lactobacillus gasseri K7 is a strain isolated from infant faeces with properties making the strain interesting for cheese production. In this study, a single reactor system was used to evaluate the survival of L. gasseri K7 and selected bifidobacteria from our collection through the stomach-intestine passage. RESULTS: Initial screening for acid resistance in acidified culture media showed a low tolerance of Bifidobacterium dentium for this condition indicating low survival in the passage. Similar results were achieved with B. longum subsp. infantis whereas B. animalis subsp. lactis had a high survival.These initial results were confirmed in the bioreactor model of the stomach-intestine passage. B. animalis subsp. lactis had the highest survival rate (10%) attaining approximately 5 x 106 cfu ml-1 compared to the other tested bifidobacteria strains which were reduced by a factor of up to 106. Lactobacillus gasseri K7 was less resistant than B. animalis subsp. lactis but survived at cell concentrations approximately 1000 times higher than other bifidobacteria.

    CONCLUSION: In this study, we were able to show that L. gasseri K7 had a high survival rate in the stomach-intestine passage. By comparing the results with a previous study in piglets we could confirm the reliability of our simulation. Of the tested bifidobacteria strains, only B. animalis subsp. lactis showed acceptable survival for a successful passage in the simulation system.
    www.ncbi.nlm.nih.gov/pubmed/19426473

    Volledig art.:
    www.db-alp.admin.ch/de/publikationen/...
  13. flosz 2 juni 2009 11:45
    Vaccine. 2009 Jun 2;27(27):3561-7. Epub 2009 Apr 10

    Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.

    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Crucell, Berna Biotech Ltd, 3018 Berne, Switzerland.

    BACKGROUND: Despite the established benefit of intramuscular (i.m.) influenza vaccination, new adjuvants and delivery methods for comparable or improved immunogenicity are being explored. Intradermal (i.d.) antigen administration is hypothesized to initiate an efficient immune response at reduced antigen doses similar to that observed after i.m. full dose vaccination.

    METHODS: In a randomized, partially blinded phase II study 224, healthy adults aged >/=18 to </=60 years were randomly assigned to four groups and received trivalent influenza vaccine at single doses of 3.0, 4.5 and 6.0mug hemagglutinin (HA) antigen of each influenza virus strain via i.d. injection or 15.0mug HA of each influenza strain via i.m. delivery. Serum anti-influenza virus antibodies were determined by hemagglutination inhibition (HI) assay before and 3 weeks after vaccination. Safety assessments were made at baseline and at the follow-up visit by the investigators and for a 4-day period post-vaccination by the subjects themselves.

    RESULTS: The EMEA requirements for re-licensing of influenza vaccines were fulfilled in all groups 3 weeks after vaccination, irrespective of dose and mode of administration. High seroconversion rates were observed in all study groups and for all strains ranging from 50.9 to 85.5% and 70.4 to 87.0% after i.d. and i.m. vaccination, respectively. Seroprotection rates for the A strains A/Solomon Islands and A/Wisconsin were generally higher compared to the B/Malaysia strain and ranged from 89.1 to 98.2% across the i.d. groups. Similar rates of 96.3% for the A/Solomon Islands and 94.4% for the A/Wisconsin strain were observed in the i.m. group. Seroprotection rates for the B/Malaysia strain were 65.5, 83.0 and 72.7% after i.d. administration of 3.0, 4.5, and 6.0mug HA of each strain, respectively, compared to a seroprotection rate of 85.2% in the i.m. group. In addition, marked increases in geometric mean titer (GMT) were observed across the groups for all influenza virus strains ranging from 6.9 to 70.5 for i.d. and from 16.9 to 56.5 for i.m. antigen delivery. Both routes of administration were well tolerated. Systemic reactions were broadly similar across the groups. With respect to local reactions the frequency of injection site pain and ecchymosis were significantly lower following i.d. vaccination, while other local reactions such as erythema occurred at higher rates with i.d. than with i.m. vaccine administration, as expected due to the mechanism of action for the i.d. route.

    CONCLUSIONS: The virosomal adjuvanted influenza vaccine (Inflexal((R))V) was shown to be overall highly immunogenic and well tolerated when given i.d. at reduced doses to healthy adults, eliciting an immune response similar to that observed with full dose i.m. administration and thus suggesting a promising antigen-sparing strategy for universal influenza vaccination against endemic influenza. TRIAL REGISTRATION: ISRCTN registry number: 33950739.
    www.ncbi.nlm.nih.gov/pubmed/19464535
  14. aossa 2 juni 2009 12:05
    "CONCLUSIONS: The virosomal adjuvanted influenza vaccine (Inflexal((R))V) was shown to be overall highly immunogenic and well tolerated when given i.d. at reduced doses to healthy adults, eliciting an immune response similar to that observed with full dose i.m. administration and thus suggesting a promising antigen-sparing strategy for universal influenza vaccination against endemic influenza."

    Dat worden dus VEEL MEER doses Inflexal V in omzet !
  15. flosz 9 juni 2009 20:10
    Molecular Therapy (2009); doi:10.1038/mt.2009.130

    New Insights on Adenovirus as Vaccine Vectors
    Marcio O Lasaro1 and Hildegund CJ Ertl1
    1The Wistar Institute Vaccine Center, Philadelphia, Pennsylvania, USA
    Correspondence: Hildegund CJ Ertl, The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA. E-mail: ertl@wistar.org
    Received 16 April 2009; Accepted 20 May 2009; Published online 9 June 2009.

    Adenovirus (Ad) vectors were initially developed for treatment of genetic diseases. Their usefulness for permanent gene replacement was limited by their high immunogenicity, which resulted in rapid elimination of transduced cells through induction of T and B cells to antigens of Ad and the transgene product. The very trait that excluded their use for sustained treatment of genetic diseases made them highly attractive as vaccine carriers. Recently though results showed that Ad vectors based on common human serotypes, such as serotype 5, may not be ideal as vaccine carriers. A recently conducted phase 2b trial, termed STEP trial, with an AdHu5-based vaccine expressing antigens of human immunodeficiency virus 1 (HIV-1) not only showed lack of efficacy in spite of the vaccine's immunogenicity, but also suggested an increased trend for HIV acquisition in individuals that had circulating AdHu5 neutralizing antibodies prior to vaccination. Alternative serotypes from humans or nonhuman primates (NHPs), to which most humans lack pre-existing immunity, have been vectored and may circumvent the problems encountered with the use of AdHu5 vectors in humans. In summary, although Ad vectors have seen their share of setbacks in recent years, they remain viable tools for prevention or treatment of a multitude of diseases.
    www.nature.com/mt/journal/vaop/ncurre...

    1. Vaccine market boosters
    Cormac Sheridan
    Nature Biotechnology 27, 499-501 (31 May 2009) doi:10.1038/nbt0609-499 News

    Recent commercial success belies conventional wisdom that vaccines are a low-margin, moribund sector. But will the trend continue? Cormac Sheridan investigates.
    www.nature.com/nbt/journal/v27/n6/abs...

    Flu vaccine makers upgrade technology—and pray for time - pp489 - 491
    Cormac Sheridan
    doi:10.1038/nbt0609-489
    www.nature.com/nbt/journal/v27/n6/ind...
  16. flosz 10 juni 2009 22:16
    quote:

    MeawandMoo1 schreef:

    Zo..
    Crucell heeft weer een antal monoclonal antibodies ontdekt met neutraliserende werking na oplopen van een infectie.
    Vergelijking met Rabies:
    Ook hier overleven de meeste muisjes na ontvangst van een dodelijke infectie.

    [quote=Crucell]
    Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo,
    [/quote]
    Human Monoclonal Antibodies Induced by Natural Infection Against West Nile Virus Neutralize at a Post-Attachment Step.

    Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS.
    Departments of Pathology and Immunology, Molecular Microbiology, Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands; Crucell Holland B.V., 2301 CA, Leiden, The Netherlands; Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

    West Nile virus (WNV) is a neurotropic flavivirus that is now a primary cause of epidemic encephalitis in North America. Studies in mice have demonstrated that the humoral immune response against WNV limits primary infection and protects against a secondary challenge. The most potent neutralizing mouse monoclonal antibodies (MAbs) recognize an epitope on the lateral ridge of domain III (DIII-lr) of the envelope (E) protein. However, studies with serum from human patients show that antibodies against the DIII-lr epitope comprise at best, a minor component of the human anti-WNV antibody response. Herein, we characterize in detail two WNV-specific human MAbs, CR4348 and CR4354, that were isolated from B cell populations of convalescent patients. These MAbs strongly neutralize WNV infection of cultured cells, protect mice against lethal infection in vivo, and yet poorly recognize recombinant forms of E protein. Instead, CR4348 and CR4354 bind determinants on intact WNV virions and subviral particles in a pH-sensitive manner, and neutralization is altered by mutations at the dimer interface in domain II and the hinge between domains I and II, respectively. CR4348 and CR4354 human MAbs neutralize infection at a post-attachment step in the viral lifecycle, likely by inhibiting acid-induced fusion within the endosome.

    www.ncbi.nlm.nih.gov/pubmed/19386704

    Uit 2006:
    jvi.asm.org/cgi/reprint/80/14/6982.pdf
  17. flosz 16 juni 2009 01:51
    quote:

    flosz schreef:

    Blood. 2009 May 8.

    Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

    Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH, Baker AH.
    British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.

    Recent studies have demonstrated the importance of coagulation factor X (FX) in adenovirus (Ad) serotype 5-mediated liver transduction in vivo. FX binds to the adenovirus hexon hypervariable regions (HVRs). Here, we perform a systematic analysis of FX binding to Ad5 HVRs 5 and 7, identifying domains and amino acids critical for this interaction. We constructed a model of the Ad5-FX interaction employing crystallographic and cryoelectron microscopic data to identify contact points. Exchanging Ad5 HVR5 or HVR7 from Ad5 to Ad26 (which does not bind FX) diminished FX binding as analysed by surface plasmon resonance, gene delivery in vitro and liver transduction in vivo. Exchanging Ad5-HVR5 for Ad26-HVR5 produced deficient virus maturation. Importantly, defined mutagenesis of just two amino acids in Ad5-HVR5 circumvented this and was sufficient to block liver gene transfer. Additionally, mutation of 4 amino acids in Ad5-HVR7 or a single mutation at position 451 also blocked FX-mediated effects in vitro and in vivo. We therefore define the regions and amino acids on the Ad5 hexon that bind with high affinity to FX thereby better defining adenovirus infectivity pathways. These vectors may be useful for gene therapy applications where evasion of liver transduction is a prerequisite.
    www.ncbi.nlm.nih.gov/pubmed/19429866

    tinyurl.com/nt3jau
  18. [verwijderd] 26 juni 2009 09:59
    Methods Mol Biol. 2009;562:45-60.

    Construction of phage antibody repertoires from the blood of west nile virus-infected donors.

    Throsby M, de Kruif J.
    Crucell Holland BV, Archimedesweg 4, 2048, 2301CA, Leiden, The Netherlands, mark.throsby@crucell.com.

    A method for the construction of West Nile virus immune donor antibody repertoires is described. B cells are harvested from a suitable donor and the antibody variable genes are amplified using polymerase chain reaction (PCR). The PCR fragments are cloned in a phage display vector to construct a repertoire that can be used in panning procedures to identify many unique monoclonal antibodies.

    www.ncbi.nlm.nih.gov/sites/entrez
127 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.160
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.502
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.931
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.892
Aedifica 3 927
Aegon 3.258 323.212
AFC Ajax 538 7.093
Affimed NV 2 6.306
ageas 5.844 109.909
Agfa-Gevaert 14 2.074
Ahold 3.538 74.361
Air France - KLM 1.025 35.329
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.068
Alfen 16 25.502
Allfunds Group 4 1.525
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.244
AMG 972 134.752
AMS 3 73
Amsterdam Commodities 305 6.754
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.106
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.093
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.379
Aroundtown SA 1 221
Arrowhead Research 5 9.758
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.697
ASML 1.767 112.199
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 523
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.343
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.463

Macro & Bedrijfsagenda

  1. 14 april

    1. Theon jaarcijfers
    2. Kendrion jaarvergadering
    3. Internationale handel februari (NL)
    4. Aalberts ex-dividend
    5. Goldman Sachs Q1-cijfers (VS)
    6. OPEC maandrapport (Oos)
  2. 15 april

    1. Ctac jaarvergadering
    2. PostNL jaarvergadering
    3. TomTom Q1-cijfers
    4. Beiersdorf Q1-cijfers (Dld)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht